NK cell dysfunction in the tumour microenvironment limits anti-tumour immunity
Natural killer (NK) cells are central components of the innate immune system, recognised for their capacity to directly eliminate tumour cells and to orchestrate broader anti-tumour immune responses. However, despite this cytotoxic potential, NK cells frequently fail to control tumour progression after entering the tumour microenvironment (TME). The study by Dean et al. (2024) examines the underlying reasons, with a focus on how NK cell function evolves following tumour infiltration.
Rapid loss of NK cell function in tumours
The study shows that NK cells rapidly lose functionality soon after entering tumours. Within 24-72 hours, NK cells exhibit reduced cytotoxic activity, diminished production of key cytokines such as IFN-γ, and a decreased ability to recruit and activate other immune cells, including dendritic cells, via chemokines such as CCL5.
This effect was consistent across multiple tumour models, indicating a general mechanism through which tumours suppress innate immune responses.
Acquisition of a tumour-retained phenotype
Over time, NK cells persisting within tumours acquire a distinct phenotype characterised by:
- Expression of CD49a, associated with tissue residency
- Loss of CD11b, a marker of mature circulating NK cells
- Increased expression of inhibitory receptors, including PD-1 and LAG-3
This transition reflects a shift from active anti-tumour effector cells to a dysfunctional, tumour-adapted population, which ultimately comprises the majority of NK cells retained in the TME.
Limited impact of tumour-resident NK cells on tumour growth
Experimental depletion of NK cells in established tumours did not significantly alter tumour growth. This finding indicates that, once rendered dysfunctional within the TME, NK cells no longer exert a measurable effect on tumour growth in these models.
Drivers of NK cell dysfunction
The study investigated several factors contributing to NK cell impairment, including:
- TGF-β signalling
- Prostaglandin E₂ (PGE₂)
- Hypoxia mediated via the HIF-1α pathway
Each factor contributed partially to NK cell dysfunction, but none alone accounted for the full phenotype. This suggests that NK cell reprogramming is driven by a combination of suppressive signals within the TME.
Evidence in human tumours
Analysis of human colorectal cancer samples revealed comparable findings:
- Tumour-infiltrating NK cells predominantly display a resting or inactive phenotype
- Reduced expression of cytotoxic mediators such as perforin and granzymes
- Enrichment of CD49a⁺ dysfunctional NK cells, particularly in advanced-stage tumours
These observations support the clinical relevance of NK cell dysfunction in human cancer.
Use of Bio x Cell antibodies in the study
Bio X Cell antibodies were used as isotype control reagents to ensure the specificity and validity of in vivo antibody-based experiments. The study utilised Bio X Cell’s InVivoMab mouse IgG2a and rat IgG2a isotype controls in combination with functional antibodies such as anti-NK1.1, anti-CD8α, and anti-OX40 from other sources.
These controls enabled accurate discrimination between specific biological effects, such as immune cell depletion or modulation, and non-specific effects associated with antibody administration. For example, comparisons between isotype-treated and depletion-treated groups were essential to demonstrate that removal of NK cells or CD8⁺ T cells led to distinct and interpretable effects on tumour growth and immune responses.
The use of Bio X Cell isotype controls ensured experimental rigour and reliable interpretation of immune intervention studies.
“To fully understand the role of NK cells in tumours, we needed an effective way to deplete these immune cells (and others) from tumours. We had access to functional antibodies to achieve this but needed suitable controls to verify the validity of results obtained. To ensure our experiments had appropriate controls we turned to Bio X Cell for their In Vivo antibodies, specifically their InVivoMab range which also consists of mouse and rat IgG isotype controls which we employed for our study. Bio X Cell have a reputation for high quality products for In Vivo use which were essential for this project, and their products remain a standard in my current research direction.”
- Dr Isaac Dean, Postdoctoral Training Fellow, Institute of Cancer Research.
Restoring NK cell activity with IL-15
A key therapeutic observation was that increased IL-15 signalling promotes the development of a distinct NK cell population with enhanced functionality. Treatment with IL-15/IL-15Rα complexes:
- Prevented the loss of NK cell function
- Increased production of cytotoxic molecules
- Induced a hybrid NK cell phenotype combining tissue residency and high activity
- Improved tumour control
Methodological approach
The study employed a photoconversion-based labelling system in transgenic mouse models to track immune cells over time within tumours. This was combined with single-cell RNA sequencing, flow cytometry, and functional cytotoxicity assays, enabling a detailed temporal map of NK cell fate from tumour entry to dysfunction.
Implications for cancer immunotherapy
- Limitations of current approaches: NK cells rapidly lose activity in tumours, potentially restricting therapies that rely on their cytotoxic function
- Targeting the TME: Enhancing NK cell recruitment alone is insufficient; suppressive signals within the TME must also be addressed
- Potential of IL-15-based strategies: IL-15 therapies may restore NK cell function and act in combination with other immunotherapies
- Understanding NK cell biology: Dysfunction appears to represent an adaptive reprogramming process rather than simple exhaustion
Conclusion
Dean et al. provide a detailed analysis of NK cell behaviour in cancer, demonstrating that these cells rapidly become dysfunctional after tumour entry and acquire a tissue-resident-like phenotype with reduced anti-tumour activity. Importantly, this impaired state is reversible, with IL-15 signalling showing the potential to restore NK cell function and improve tumour control.
These findings identify both a significant obstacle to effective anti-tumour immunity and a promising direction for enhancing immunotherapy by reactivating innate immune responses within the tumour microenvironment.
Reference
Dean, I., Lee, C.Y.C., Tuong, Z.K. et al. Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity. Nat Commun 15, 683 (2024). doi.org/10.1038/s41467-024-44789-z
Featured supplier
Zymo Research
Zymo Research is a leader in molecular biology, offering a comprehensive range of products for DNA, RNA, and epigenetics research. Established in California in 1994, the company is renowned for its high-quality nucleic acid purification technologies, including kits and reagents for DNA and RNA clean-up, isolation, and sequencing. Zymo is also a pioneer in epigenetics, with products for DNA methylation analysis, chromatin analysis, and NGS library preparation. Each product is designed to be simple to use, reliable, and available at competitive prices, making them ideal for both academic and biopharmaceutical research.